Invesco Pharmaceuticals ETF

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

WGRX

Wellgistics Health, Inc. reported Q1 2026 revenue of $1.56M, down 85.6% from $10.86M a year ago, with a net loss of $7.74M, an improvement from a $32.43M loss in the previous year. The decline in revenue was attributed to reduced distribution activity and liquidity issues, while pharmacy retail sales increased. The company completed acquisitions to enhance its healthcare ecosystem and is investing in sales and marketing to boost brand awareness and customer acquisition.

TradingView

Wellgistics Health

iShares US Pharma

SPDR Pharmac

VanEck Pharmaceutical ETF

Wellgistics Health, Inc. 1Q 2026: Revenue $1.56M, EPS ($0.07) — 10-Q Summary

Wellgistics Health reported a significant increase in monthly revenue for its pharmacy segment, rising from $0.1 million in November 2025 to $0.6 million in April 2026. The company is focusing on expanding its direct-to-patient initiatives and integrating new technologies. It has terminated previous non-binding agreements and is in discussions to enhance its PharmacyChain™ capabilities. The first quarter of 2026 saw a net operating loss of $7.742 million, a decrease from the previous year, attributed to cost-cutting measures.

StockTitan

Datavault AI

Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update | WGRX Stock News

Wellgistics Health Inc. will release its Q1 2026 earnings on May 19, 2026, after market close. The update will provide insights into the performance of its AI-driven pharmacy platform and blockchain distribution model, which connects over 6,500 pharmacies with 200 manufacturers. This earnings report is anticipated to influence investor perceptions regarding the company's competitive position and growth potential in the healthcare sector.

Tip Ranks

Wellgistics Health Schedules First-Quarter 2026 Earnings Release

Cardinal Health Inc. (CAH) shares rose 2.34% to $199.77 on a mixed trading day, marking its fifth consecutive gain. The stock remains 14.48% below its 52-week high of $233.60. Competitors had varied performances, with Amazon up 0.27%, UnitedHealth down 0.69%, and CVS up 0.10%. Trading volume reached 2.4 million, surpassing the 50-day average of 2.0 million.

MarketWatch Automated

Cardinal Health

SPDR S&P Health Equip

iShares US Medical Devices

Dow Jones Industrial Average

S&P 500

Amazon

Unitedhealth

CVS Health

Cardinal Health Inc. Stock Outperforms Competitors On Strong Trading Day

LABU

McKesson (MCK) reported strong Q4 and full year earnings, with increased sales and net income, leading to a 1.79% rise in stock price to $760.57. Despite recent declines, long-term returns remain robust. Analysts suggest the stock is undervalued at $951.73, driven by earnings power and acquisitions. However, a DCF model indicates potential downside risk, emphasizing the need to weigh earnings against cash generation. Investors are encouraged to explore other opportunities in healthcare.

Simplywall

McKesson

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Cencora's fiscal Q2 2026 results revealed higher sales of $78.36 billion and net income of $1.64 billion, but a revenue miss and lowered growth outlook have raised concerns about its margin expansion narrative. The company confirmed a 4% to 6% revenue growth guidance for 2026, but ongoing investigations and pricing pressures could impact margins. Analysts are cautious, with some projecting only 4.5% annual growth. Cencora's future performance will be critical in restoring investor confidence and shaping its stock sentiment.

Cencora

Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?

Pomerantz Law Firm is investigating claims for investors of Cencora, Inc. (NYSE: COR) regarding potential securities fraud by the company and its officers. Following Cencora's Q2 2026 results, which missed revenue estimates and lowered growth guidance, the stock price dropped 17.4%. Investors are encouraged to contact Pomerantz for more information.

prnewswire

22:25 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

Cencora Inc. (COR) shares rose 2.12% to $261.11 on a strong trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. The S&P 500 and Dow Jones also saw gains of 0.77% and 0.75%, respectively. Despite the increase, Cencora remains 30.84% below its 52-week high of $377.54 reached on November 25. Trading volume was significantly higher than its 50-day average.

Factset Research

Cencora Inc. Stock Outperforms Competitors On Strong Trading Day

McKesson Corp. (MCK) shares rose 1.36% to $747.23 on a positive trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. This marks the third consecutive day of gains for McKesson, although it remains 25.20% below its 52-week high of $999.00 reached on March 3rd. The trading volume was 921,594, surpassing the 50-day average of 909,974.

McKesson Corp. Stock Outperforms Competitors On Strong Trading Day

NXPL

NextPlat (NASDAQ:NXPL) reported its Q1 2026 financial results, highlighting significant margin expansion and improved profitability, primarily from its healthcare operations, which contributed 68% of revenue. The company regained compliance with NASDAQ's minimum bid requirement after a reverse stock split. Gross margin increased to 35% from 21% year-over-year, driven by higher-margin revenue streams. NextPlat ended the quarter with $11 million in cash and no significant debt, focusing on sustaining profitability and exploring growth through potential joint ventures or acquisitions.

Invesco Pharmaceuticals ETF(PJP.US)